| |
|
|
|
|
| November 12 ,
2009 | ISSUE NUMBER 124 VOL 6 |
Restructuring
Pfizer Quick on the Draw with R&D Location Plans
Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network.
Stategy
GSK Donates 50 Million H1N1 Doses To WHO
Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world.
HR
Roche: New Hires Needed
With an acquisition underway, major career opportunities have opened up at one of the company’s main R&D centers. Here’s how HR is handling recruitment amidst a time of organizational change.
Specialty Medicines
The Case for Specialty Medicines: Is Industry Credible, or Culpable?
Pharma is pinning its hopes on innovative, high-priced, difficult-to-manufacture drugs that focus on unmet clinical needs. But is industry chasing a “new” model that’s already passé?
Advertisement:
Imagine a digital identity and signature standard for the pharmaceutical industry
Imagine no more. Faced with numerous proprietary electronic applications and standards, the pharmaceutical industry saw a critical need for a global, interoperable, digital identity and signature standard. That’s why the SAFE-BioPharma Association was formed. Watch this
 video to learn how worldwide pharmaceutical companies and their partners are working to establish a digital identity and signature standard recognized by regulatory and legal authorities around the world.
|
Global
The Trouble with Transparency
If the UK’s MP expenses furor is anything to go by, pharma’s ongoing move toward transparency could see some stormy times ahead.
Guest Blog
Transformational Analytics Will Set You Free
Without committed leadership from the top of an organization, the best answers will not see the light of day, and the “my number is better than yours” issue will persist.
Podcast
Emerging Pharma Leadership Awards—Paulash Mohsen, Pfizer
Paulash Mohsen, vice president, primary care strategy for Pfizer, talks about changes in the pharmaceutical environment and what industry might do to best adapt.
New & Noteworthy
Are You Ready For The Revolution?
Seven global trends shaping the future of the pharmaceutical industry. |
Advertisement:
CBI’s 8th Annual Commercialization Strategies for Pharmaceutical Product Launches – December 8–9, 2009, Philadelphia, PA
Leverage Successful Product Planning, Marketing, Pricing and Reimbursement Strategies for Accelerated Product Uptake
Save $400 off of your registration fee!* Mention promotional code QDD993 when registering.
Call 800-817-8601 or visit
 www.cbinet.com/ProductLaunchEast
*Discount offer can not be combined with other discounts or applied to a current registration.
Offer not valid on workshop only or academic registrations.
|
 |
|  Amicus Therapeutics appointed Margaret G. McGlynn to its board of directors // Cipher Pharmaceuticals apponted William Claypool to its board of directors // Cornerstone Pharmaceuticals made Robert C. Shepard chief medical officer // Bionovo appointed Steven R. Goldstein to its medical advisory board // NeurogesX named Timothy Arendt vice president sales; Amy C. Cavers senior director of marketing; and Linda L. Schock director of commercial operations // Wolters Kluwer Health appointed Anne Dabrow Woods to chief nursing officer
Core-Create named Melanie Shiel senior art director // Santen President and CEO Adrienne L. Graves, was appointed to the board of directors of the Glaucoma Research Foundation //
|
December 2 Risk, Reward and the Pharmaceutical Life Cycle: Managing Information as a Strategic Productivity Asset
Wednesday, December 2, 2009 at 11AM ET
December 3 Building Market Share Through Patient Segmentation Strategies: New Ideas and Best Practices to Enhance ROI
Thursday, December 3, 2009 at 11:30 AM ET
Register Free at www.pharmexec.com/marketshare
December 8 How Virtual Media Can Save the Medical Speaker Program
Tuesday, December 8, 2009 at 11:00 AM ET
Register Free at www.medpt.com/pharmexec/speaker
|
|
|
Nov 17–18, 2009 3rd Annual Evidence-Based Medicine and Comparative Effectiveness Research Summit for the Bio/Pharmaceutical and Medical Device Industries,
Philadelphia, PA
Dec 8–9, 2009 Forum on FDA’s Structured Product Labeling, Washington, DC
Jan 21–22, 2010 Bio/Pharmaceutical Forum on Optimizing the Use of Complex Data Assets,
Philadelphia, PA
Jan 25–26, 2010 Bio/Pharmaceutical Forum on Strategic Sourcing and Procurement,
Philadelphia, PA
Feb 8–9, 2010 3rd Annual Clinical Trial Forecasting and Budgeting, Philadelphia, PA |
|
|
|
 |
|
 |
|
 |
| Should FDA recognize social media as a new form of communication with its own rules and regulations? |
|
|
|
|
You are subscribed to Pharm Exec Direct..
To unsubscribe,
click here
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
